NASDAQ:CLPT

ClearPoint Neuro Competitors

$22.12
-0.43 (-1.91 %)
(As of 04/9/2021 12:00 AM ET)
Add
Compare
Today's Range
$21.15
Now: $22.12
$22.70
50-Day Range
$17.34
MA: $21.28
$25.80
52-Week Range
$2.90
Now: $22.12
$31.29
Volume299,200 shs
Average Volume462,858 shs
Market Capitalization$457.29 million
P/E RatioN/A
Dividend YieldN/A
Beta1.15

Competitors

ClearPoint Neuro (NASDAQ:CLPT) Vs. INO, GNMK, SILK, ATEC, LMNX, and LUNG

Should you be buying CLPT stock or one of its competitors? Companies in the industry of "surgical & medical instruments" are considered alternatives and competitors to ClearPoint Neuro, including Inovio Pharmaceuticals (INO), GenMark Diagnostics (GNMK), Silk Road Medical (SILK), Alphatec (ATEC), Luminex (LMNX), and Pulmonx (LUNG).

ClearPoint Neuro (NASDAQ:CLPT) and Inovio Pharmaceuticals (NASDAQ:INO) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, dividends, profitability, analyst recommendations, earnings, valuation and risk.

Profitability

This table compares ClearPoint Neuro and Inovio Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
ClearPoint Neuro-55.55%-309.91%-34.06%
Inovio Pharmaceuticals-8,518.10%-78.17%-40.33%

Risk and Volatility

ClearPoint Neuro has a beta of 1.15, indicating that its share price is 15% more volatile than the S&P 500. Comparatively, Inovio Pharmaceuticals has a beta of 1.08, indicating that its share price is 8% more volatile than the S&P 500.

Valuation & Earnings

This table compares ClearPoint Neuro and Inovio Pharmaceuticals' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ClearPoint Neuro$11.22 million40.76$-5,540,000.00($0.42)-52.67
Inovio Pharmaceuticals$4.11 million441.95$-119,360,000.00($1.16)-7.52

ClearPoint Neuro has higher revenue and earnings than Inovio Pharmaceuticals. ClearPoint Neuro is trading at a lower price-to-earnings ratio than Inovio Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of recent ratings and price targets for ClearPoint Neuro and Inovio Pharmaceuticals, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
ClearPoint Neuro00203.00
Inovio Pharmaceuticals14302.25

ClearPoint Neuro presently has a consensus price target of $35.00, indicating a potential upside of 58.23%. Inovio Pharmaceuticals has a consensus price target of $17.00, indicating a potential upside of 94.95%. Given Inovio Pharmaceuticals' higher probable upside, analysts clearly believe Inovio Pharmaceuticals is more favorable than ClearPoint Neuro.

Institutional and Insider Ownership

6.6% of ClearPoint Neuro shares are owned by institutional investors. Comparatively, 36.0% of Inovio Pharmaceuticals shares are owned by institutional investors. 9.2% of ClearPoint Neuro shares are owned by insiders. Comparatively, 4.0% of Inovio Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

ClearPoint Neuro beats Inovio Pharmaceuticals on 8 of the 14 factors compared between the two stocks.

GenMark Diagnostics (NASDAQ:GNMK) and ClearPoint Neuro (NASDAQ:CLPT) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, analyst recommendations, profitability, risk, earnings, dividends and institutional ownership.

Valuation and Earnings

This table compares GenMark Diagnostics and ClearPoint Neuro's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
GenMark Diagnostics$88.02 million19.92$-47,350,000.00($0.82)-29.26
ClearPoint Neuro$11.22 million40.76$-5,540,000.00($0.42)-52.67

ClearPoint Neuro has lower revenue, but higher earnings than GenMark Diagnostics. ClearPoint Neuro is trading at a lower price-to-earnings ratio than GenMark Diagnostics, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of current recommendations for GenMark Diagnostics and ClearPoint Neuro, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
GenMark Diagnostics05002.00
ClearPoint Neuro00203.00

GenMark Diagnostics presently has a consensus price target of $22.0125, indicating a potential downside of 8.24%. ClearPoint Neuro has a consensus price target of $35.00, indicating a potential upside of 58.23%. Given ClearPoint Neuro's stronger consensus rating and higher probable upside, analysts clearly believe ClearPoint Neuro is more favorable than GenMark Diagnostics.

Profitability

This table compares GenMark Diagnostics and ClearPoint Neuro's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
GenMark Diagnostics-16.95%-39.36%-13.02%
ClearPoint Neuro-55.55%-309.91%-34.06%

Institutional and Insider Ownership

96.9% of GenMark Diagnostics shares are owned by institutional investors. Comparatively, 6.6% of ClearPoint Neuro shares are owned by institutional investors. 3.3% of GenMark Diagnostics shares are owned by company insiders. Comparatively, 9.2% of ClearPoint Neuro shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Volatility & Risk

GenMark Diagnostics has a beta of 3.02, suggesting that its stock price is 202% more volatile than the S&P 500. Comparatively, ClearPoint Neuro has a beta of 1.15, suggesting that its stock price is 15% more volatile than the S&P 500.

Summary

ClearPoint Neuro beats GenMark Diagnostics on 8 of the 14 factors compared between the two stocks.

ClearPoint Neuro (NASDAQ:CLPT) and Silk Road Medical (NASDAQ:SILK) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, profitability, analyst recommendations, institutional ownership, dividends, valuation and earnings.

Valuation & Earnings

This table compares ClearPoint Neuro and Silk Road Medical's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ClearPoint Neuro$11.22 million40.76$-5,540,000.00($0.42)-52.67
Silk Road Medical$63.35 million27.20$-52,420,000.00($1.36)-36.87

ClearPoint Neuro has higher earnings, but lower revenue than Silk Road Medical. ClearPoint Neuro is trading at a lower price-to-earnings ratio than Silk Road Medical, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

ClearPoint Neuro has a beta of 1.15, indicating that its share price is 15% more volatile than the S&P 500. Comparatively, Silk Road Medical has a beta of 1.41, indicating that its share price is 41% more volatile than the S&P 500.

Profitability

This table compares ClearPoint Neuro and Silk Road Medical's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
ClearPoint Neuro-55.55%-309.91%-34.06%
Silk Road Medical-53.66%-40.79%-24.56%

Analyst Recommendations

This is a breakdown of recent recommendations for ClearPoint Neuro and Silk Road Medical, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
ClearPoint Neuro00203.00
Silk Road Medical02202.50

ClearPoint Neuro presently has a consensus target price of $35.00, suggesting a potential upside of 58.23%. Silk Road Medical has a consensus target price of $61.75, suggesting a potential upside of 23.16%. Given ClearPoint Neuro's stronger consensus rating and higher possible upside, equities analysts plainly believe ClearPoint Neuro is more favorable than Silk Road Medical.

Insider and Institutional Ownership

6.6% of ClearPoint Neuro shares are held by institutional investors. 9.2% of ClearPoint Neuro shares are held by company insiders. Comparatively, 7.8% of Silk Road Medical shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

ClearPoint Neuro beats Silk Road Medical on 7 of the 13 factors compared between the two stocks.

ClearPoint Neuro (NASDAQ:CLPT) and Alphatec (NASDAQ:ATEC) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, risk, earnings, profitability, valuation, analyst recommendations and institutional ownership.

Earnings and Valuation

This table compares ClearPoint Neuro and Alphatec's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ClearPoint Neuro$11.22 million40.76$-5,540,000.00($0.42)-52.67
Alphatec$113.43 million14.76$-57,000,000.00($1.09)-16.15

ClearPoint Neuro has higher earnings, but lower revenue than Alphatec. ClearPoint Neuro is trading at a lower price-to-earnings ratio than Alphatec, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

ClearPoint Neuro has a beta of 1.15, indicating that its stock price is 15% more volatile than the S&P 500. Comparatively, Alphatec has a beta of 1.53, indicating that its stock price is 53% more volatile than the S&P 500.

Profitability

This table compares ClearPoint Neuro and Alphatec's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
ClearPoint Neuro-55.55%-309.91%-34.06%
Alphatec-51.95%-266.45%-40.80%

Analyst Ratings

This is a breakdown of recent recommendations and price targets for ClearPoint Neuro and Alphatec, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
ClearPoint Neuro00203.00
Alphatec00703.00

ClearPoint Neuro currently has a consensus target price of $35.00, suggesting a potential upside of 58.23%. Alphatec has a consensus target price of $15.4286, suggesting a potential downside of 12.34%. Given ClearPoint Neuro's higher possible upside, equities research analysts clearly believe ClearPoint Neuro is more favorable than Alphatec.

Insider & Institutional Ownership

6.6% of ClearPoint Neuro shares are owned by institutional investors. Comparatively, 31.8% of Alphatec shares are owned by institutional investors. 9.2% of ClearPoint Neuro shares are owned by company insiders. Comparatively, 28.2% of Alphatec shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Alphatec beats ClearPoint Neuro on 8 of the 13 factors compared between the two stocks.

ClearPoint Neuro (NASDAQ:CLPT) and Luminex (NASDAQ:LMNX) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, risk, earnings, profitability, valuation, analyst recommendations and institutional ownership.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for ClearPoint Neuro and Luminex, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
ClearPoint Neuro00203.00
Luminex00103.00

ClearPoint Neuro currently has a consensus target price of $35.00, suggesting a potential upside of 58.23%. Luminex has a consensus target price of $38.00, suggesting a potential upside of 15.33%. Given ClearPoint Neuro's higher possible upside, equities research analysts clearly believe ClearPoint Neuro is more favorable than Luminex.

Insider & Institutional Ownership

6.6% of ClearPoint Neuro shares are owned by institutional investors. Comparatively, 88.1% of Luminex shares are owned by institutional investors. 9.2% of ClearPoint Neuro shares are owned by company insiders. Comparatively, 9.4% of Luminex shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Earnings and Valuation

This table compares ClearPoint Neuro and Luminex's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ClearPoint Neuro$11.22 million40.76$-5,540,000.00($0.42)-52.67
Luminex$334.64 million4.66$-3,840,000.00($0.21)-156.90

Luminex has higher revenue and earnings than ClearPoint Neuro. Luminex is trading at a lower price-to-earnings ratio than ClearPoint Neuro, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

ClearPoint Neuro has a beta of 1.15, indicating that its stock price is 15% more volatile than the S&P 500. Comparatively, Luminex has a beta of 0.61, indicating that its stock price is 39% less volatile than the S&P 500.

Profitability

This table compares ClearPoint Neuro and Luminex's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
ClearPoint Neuro-55.55%-309.91%-34.06%
Luminex4.60%3.75%2.73%

Summary

Luminex beats ClearPoint Neuro on 9 of the 13 factors compared between the two stocks.

Pulmonx (NASDAQ:LUNG) and ClearPoint Neuro (NASDAQ:CLPT) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, dividends, profitability, analyst recommendations, institutional ownership, risk and valuation.

Insider and Institutional Ownership

6.6% of ClearPoint Neuro shares are owned by institutional investors. 9.2% of ClearPoint Neuro shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares Pulmonx and ClearPoint Neuro's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
PulmonxN/AN/AN/A
ClearPoint Neuro-55.55%-309.91%-34.06%

Analyst Recommendations

This is a summary of recent ratings and target prices for Pulmonx and ClearPoint Neuro, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Pulmonx03502.63
ClearPoint Neuro00203.00

Pulmonx currently has a consensus target price of $58.00, suggesting a potential upside of 33.39%. ClearPoint Neuro has a consensus target price of $35.00, suggesting a potential upside of 58.23%. Given ClearPoint Neuro's stronger consensus rating and higher possible upside, analysts plainly believe ClearPoint Neuro is more favorable than Pulmonx.

Earnings & Valuation

This table compares Pulmonx and ClearPoint Neuro's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Pulmonx$32.60 million47.60$-20,700,000.00N/AN/A
ClearPoint Neuro$11.22 million40.76$-5,540,000.00($0.42)-52.67

ClearPoint Neuro has lower revenue, but higher earnings than Pulmonx.

Summary

Pulmonx beats ClearPoint Neuro on 6 of the 11 factors compared between the two stocks.


ClearPoint Neuro Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Inovio Pharmaceuticals logo
INO
Inovio Pharmaceuticals
1.4$8.72-0.9%$1.82 billion$4.11 million-6.41
GenMark Diagnostics logo
GNMK
GenMark Diagnostics
1.5$23.99-0.2%$1.75 billion$88.02 million-58.51
Silk Road Medical logo
SILK
Silk Road Medical
1.1$50.14-0.7%$1.72 billion$63.35 million-41.10
Alphatec logo
ATEC
Alphatec
0.8$17.60-1.3%$1.67 billion$113.43 million-16.00Analyst Report
Luminex logo
LMNX
Luminex
1.8$32.95-2.0%$1.56 billion$334.64 million84.49
Pulmonx logo
LUNG
Pulmonx
1.4$43.48-4.7%$1.55 billion$32.60 million0.00Insider Selling
Gap Down
Cardiovascular Systems logo
CSII
Cardiovascular Systems
1.7$36.13-0.8%$1.45 billion$236.54 million-54.74
MiMedx Group logo
MDXG
MiMedx Group
1.7$12.72-5.0%$1.42 billion$299.26 million-13.53
Atrion logo
ATRI
Atrion
1.1$644.00-0.3%$1.18 billion$155.07 million36.28
SI-BONE logo
SIBN
SI-BONE
1.2$33.76-0.5%$1.10 billion$67.30 million-21.10
Tactile Systems Technology logo
TCMD
Tactile Systems Technology
1.2$54.00-0.9%$1.06 billion$189.49 million-120.00
LeMaitre Vascular logo
LMAT
LeMaitre Vascular
1.9$51.44-2.0%$1.06 billion$117.23 million55.31
Cerus logo
CERS
Cerus
1.7$6.13-1.0%$1.03 billion$74.65 million-15.72Analyst Revision
OrthoPediatrics logo
KIDS
OrthoPediatrics
1.5$49.55-0.0%$974.05 million$72.55 million-34.41
AngioDynamics logo
ANGO
AngioDynamics
1.4$23.77-1.7%$906.52 million$264.16 million-5.32
CryoLife logo
CRY
CryoLife
2.0$22.61-0.1%$884.50 million$276.22 million-59.50
Orthofix Medical logo
OFIX
Orthofix Medical
1.2$42.87-1.6%$836.48 million$459.95 million35.73
Surmodics logo
SRDX
Surmodics
1.3$57.14-0.9%$786.02 million$94.86 million714.25
OraSure Technologies logo
OSUR
OraSure Technologies
1.7$10.42-0.3%$749.68 million$154.60 million-45.30
Antares Pharma logo
ATRS
Antares Pharma
1.8$4.10-0.5%$689.46 million$123.86 million68.34
Intersect ENT logo
XENT
Intersect ENT
1.4$20.49-1.7%$676.50 million$109.14 million-10.73
SeaSpine logo
SPNE
SeaSpine
1.3$21.94-2.1%$612.85 million$159.08 million-13.14Analyst Revision
Gap Down
Vapotherm logo
VAPO
Vapotherm
1.5$23.26-0.7%$600.27 million$48.10 million-11.08
Anika Therapeutics logo
ANIK
Anika Therapeutics
1.5$39.80-1.7%$570.33 million$114.51 million-84.68
Pulse Biosciences logo
PLSE
Pulse Biosciences
1.5$21.81-1.0%$568.96 millionN/A-9.61
PAVmed logo
PAVM
PAVmed
1.2$6.00-1.8%$494.77 millionN/A-7.89
Accuray logo
ARAY
Accuray
2.3$5.21-0.6%$484.00 million$382.93 million37.21
iCAD logo
ICAD
iCAD
1.5$18.55-1.0%$462.23 million$31.34 million-19.53Analyst Downgrade
AVITA Medical logo
RCEL
AVITA Medical
1.4$21.07-0.2%$455.72 million$14.26 million-10.18Analyst Downgrade
Profound Medical logo
PROF
Profound Medical
1.6$20.50-3.9%$415.95 million$4.17 million-17.52
Soliton logo
SOLY
Soliton
1.1$18.25-0.1%$386.90 millionN/A-24.33
Cytosorbents logo
CTSO
Cytosorbents
1.7$8.90-0.2%$385.05 million$24.95 million-26.97
UFP Technologies logo
UFPT
UFP Technologies
1.3$49.73-0.7%$373.97 million$198.38 million24.87
Acutus Medical logo
AFIB
Acutus Medical
1.3$13.20-0.5%$370.85 million$2.84 million0.00
Apyx Medical logo
APYX
Apyx Medical
1.0$9.50-3.7%$326.02 million$28.15 million-20.21
Neuronetics logo
STIM
Neuronetics
1.5$12.79-2.5%$324.97 million$62.66 million-7.61
Utah Medical Products logo
UTMD
Utah Medical Products
0.9$87.54-1.0%$319.17 million$46.90 million27.62
DarioHealth logo
DRIO
DarioHealth
1.1$20.62-3.9%$317.45 million$7.56 million-2.58
IRadimed logo
IRMD
IRadimed
1.5$24.04-3.0%$295.96 million$38.52 million75.13
Co-Diagnostics logo
CODX
Co-Diagnostics
1.6$9.10-2.2%$260.86 million$220,000.0011.23
T2 Biosystems logo
TTOO
T2 Biosystems
1.4$1.53-0.7%$227.19 million$8.34 million-2.22
Titan Medical logo
TMDI
Titan Medical
1.2$1.82-7.1%$199.34 millionN/A182.00Analyst Revision
News Coverage
TELA Bio logo
TELA
TELA Bio
2.1$13.72-0.0%$198.12 million$15.45 million-4.71
NMRD
Nemaura Medical
0.2$6.96-3.6%$159.59 millionN/A-34.80
PolyPid logo
PYPD
PolyPid
1.4$9.33-2.0%$159.04 millionN/A0.00
Repro Med Systems logo
KRMD
Repro Med Systems
2.0$3.44-0.6%$153.00 million$23.16 million-344.00
Apollo Endosurgery logo
APEN
Apollo Endosurgery
1.9$5.66-1.1%$147.07 million$50.71 million-4.56
Lyra Therapeutics logo
LYRA
Lyra Therapeutics
1.6$11.20-1.0%$145.02 millionN/A0.00News Coverage
Avinger logo
AVGR
Avinger
1.3$1.50-0.7%$142.95 million$9.13 million-1.15
Beyond Air logo
XAIR
Beyond Air
1.7$5.95-1.8%$121.90 million$1.39 million-3.79
This page was last updated on 4/12/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.